Abiopharma

Alterity Therapeutics Limited (ATHE) Files Form 6-K

Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

BrainsWay Announces First Coverage Policy for Accelerated Deep TMS™

BRAINSWAY (BWAY) Files Form 6-K

Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China

Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum

TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Sotera Health to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy

GSK plc (GLAXF) Files Form 6-K

(90% Positive) MONTE ROSA THERAPEUTICS, INC. (GLUE) Provides Update on development for today at 8 a

Genprex Provides Clinical Update on Diabetes Gene Therapy Program

10x Genomics - CareDx and 10x Genomics to LaunchImmuneScape™ Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug Response